From: Effects of paliperidone extended release on the symptoms and functioning of schizophrenia
Preferred Term | N = 426 N (%) |
---|---|
Patients with any Adverse Event | 213 (50.0%) |
Disease progression | 33 (7.7%)* |
Upper respiratory tract infection | 30 (7.0%) |
Extrapyramidal disorder | 22 (5.2%) |
Insomnia | 17 (4.0%) |
Constipation | 14 (3.3%) |
Anxiety | 11 (2.6%) |
Nasopharyngitis | 11 (2.6%) |
Diarrhoea | 9 (2.1%) |
Headache | 9 (2.1%) |
Somnolence | 9 (2.1%) |
Tachycardia | 9 (2.1%) |